Breaking News Instant updates and real-time market news.

ARWR

Arrowhead

$36.61

2.11 (6.12%)

, AMGN

Amgen

$203.60

0.32 (0.16%)

18:43
10/17/19
10/17
18:43
10/17/19
18:43

Arrowhead CEO: We can silence a single gene

In an interview on CNBC's Mad Money, Arrowhead CEO Christopher Anzalone said: We have great partnerships with large companies such as Amgen (AMGN) and Johnson & Johnson (JNJ)...We can silence a single gene - we know it works and we can do it in a well-tolerated manner... We focus on validated targets.

ARWR

Arrowhead

$36.61

2.11 (6.12%)

AMGN

Amgen

$203.60

0.32 (0.16%)

JNJ

Johnson & Johnson

$136.20

1 (0.74%)

  • 29

    Oct

  • 06

    Nov

  • 07

    Dec

ARWR Arrowhead
$36.61

2.11 (6.12%)

08/06/19
PIPR
08/06/19
NO CHANGE
Target $50
PIPR
Overweight
Arrowhead price target raised to $50 from $33 at Piper Jaffray
Piper Jaffray analyst Edward Tenthoff raised his price target for Arrowhead Pharmaceuticals to $50 from $33 and reiterates an Overweight rating on the shares following the company's fiscal Q3 results. Arrowhead ended the quarter with cash of $295M and could soon receive a $25M milestone from Janssen for initiating Phase II REEF-1 study of JNJ-3989, Tenthoff tells investors in a research note. The analyst sees the cash position advancing Arrowhead's wholly-owned TRiM pipeline.
10/03/19
10/03/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Incyte (INCY) initiated with a Buy at Mizuho. 2. Lyft (LYFT) and Uber (UBER) initiated with a Neutral at MKM Partners. 3. Arrowhead (ARWR) initiated with an Outperform at Baird. 4. United Technologies (UTX) initiated with an Outperform at Credit Suisse. 5. Ulta Beauty (ULTA) initiated with a Neutral at Goldman Sachs. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
10/02/19
BARD
10/02/19
INITIATION
Target $39
BARD
Outperform
Arrowhead initiated with an Outperform at Baird
Baird analyst Madhu Kumar initiated Arrowhead with an Outperform rating and $39 price target.
09/16/19
PIPR
09/16/19
NO CHANGE
Target $50
PIPR
Overweight
Arrowhead to initiate Phase II/III Sequoia trial this year, says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $50 price target on Arrowhead Pharmaceuticals after the company presented first in man data for ARO-APOC3 and ARO-ANG3 at the Global Summit on Cardiology and Heart Diseases in Dubai. In a research note to investors, Tenthoff syas that in healthy volunteers, single doses of ARO-APOC3 resulted in 66% lowering of triglycerides and 63% for ARO-ANG3 through week 12. He looks for Arrowhead to initiate the Phase II/III SEQUOIA trial of ARO-AAT and file CTAs on two additional TRiM candidates ARO-HIF2 and ARO-HSD this year.
AMGN Amgen
$203.60

0.32 (0.16%)

10/09/19
SBSH
10/09/19
NO CHANGE
Target $130
SBSH
Buy
Mirati Q4 data could send stock 'meaningfully higher,' says Citi
Citi analyst Yigal Nochomovitz continues to have favorable expectations for Mirati Therapeutics' (MTRX) initial MRTX849 data in Q4 and believes that a response rate in non-small-cell lung carcinoma in line with Amgen's (AMGN) ~50% should drive the stock "meaningfully higher." In addition, given the small sample size, the analyst believes that a slightly lower potential response rate, like in the 35%-40% range, "should not by default be viewed as inferior." He keeps a Buy rating on Mirati shares with a $130 price target.
10/14/19
BERN
10/14/19
INITIATION
BERN
Outperform
Amgen resumed with an Outperform at Bernstein
Bernstein analyst Aaron Gal resumed coverage of Amgen with an Outperform rating. His analysis of the U.S. infused oncology market suggests biosimilars will be quickly adopted. The analyst believes Amgen looks "especially well-positioned" with existing commercial infrastructure, early entry on Herceptin and Avastin, familiarity with dynamics from defending Neulasta. When EU adoption is added, this business adds10% to Amgen top line, he contends.
09/30/19
JPMS
09/30/19
NO CHANGE
JPMS
Neutral
Amgen colorectal cancer update 'underwhelming,' says JPMorgan
Amgen's updated AMG 510 KRAS data presented over the weekend did little to boost expectations for monotherapy treatment in colorectal cancer, JPMorgan analyst Cory Kasimov tells investors in a research note. Most of the early enthusiasm for the KRAS class is for lung cancer, and this is likely to remain the case for the time being, adds the analyst. He views Amgen's weekend update as "underwhelming" and keeps a Neutral rating on the shares. Kasimov thinks the colorectal cancer indication will ultimately require a combo approach.
10/16/19
BOFA
10/16/19
INITIATION
Target $215
BOFA
Neutral
Amgen reinstated with a Neutral at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Amgen with a Neutral rating and $215 price target. The analyst has a "general lack of enthusiasm over the growth profile due to erosion from legacy brands," but also sees a promising, early stage pipeline for Amgen.
JNJ Johnson & Johnson
$136.20

1 (0.74%)

10/11/19
BERN
10/11/19
UPGRADE
Target $155
BERN
Outperform
Bernstein upgrades 'historically cheap' Johnson & Johnson to Outperform
Bernstein analyst Lee Hambright upgraded Johnson & Johnson to Outperform from Market Perform with a price target of $155, up from $148. The shares in premarket trading are up $1.94, or 1.5%, to $131. The stock is "historically cheap," currently trading at a 17% discount to its sum-of-the-parts and a 13% discount to the S&P 500 Index, Hambright tells investors in a research note. The analyst, who believes J&J will resolve its legal liability for $10B-$12B, says the shares reflect a worst case scenario with $50B of liabilities being priced in. Following discussions with legal experts, Hambright has a "hard time seeing the worst-case scenarios playing out." The analyst estimates Johnson & Johnson faces about $5B of liability for opioids, another $5B for talc, and $800M for Risperdal.
10/16/19
10/16/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Johnson & Johnson (JNJ) upgraded to Neutral from Underweight at Atlantic Equities. 2. FMC Corporation (FMC) upgraded to Outperform from Neutral at Baird with analyst Ben Kallo saying he believes FMC's new product introductions, expected share gains in key markets, and operating leverage can drive revenue and adjusted EBITDA growth in 2020 and beyond. 3. Pure Storage (PSTG) upgraded to Outperform from Market Perform at Raymond James with analyst Simon Leopold saying recent VAR/Distributor checks have reflected positive sentiment suggesting Pure can exceed current Street estimates and he has gained a greater appreciation for the market expansion offered by the new FlashArray//C. 4. PDF Solutions (PDFS) upgraded to Buy from Hold at Craig-Hallum with analyst Christian Schwab saying PDF Solutions is transitioning the company to an analytics software model, and believes that looking out 3-5 years, and in line with management's long term model shared at the company's Analyst Day, it can become a "Rule of 40" SaaS like company with 70% gross margins and in aggregate a 20% top line growth rate and 20% operating margin. 5. Builders FirstSource (BLDR) and BMC Stock Holdings (BMCH) upgraded to Overweight from Equal Weight at Stephens. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/16/19
JPMS
10/16/19
NO CHANGE
Target $38
JPMS
Overweight
JPMorgan boosts Jabil target to $38 on key customer momentum
JPMorgan analyst Paul Coster raised his price target for Jabil (JBL) to $38 from $36 and keeps an Overweight rating on the shares. The analyst increased Jabil's price-to-earnings multiple to reflect positive momentum at key end customers Johnson & Johnson (JNJ) and Apple (AAPL), and to reflect near-term prospects for a hiatus in the trade conflict between the U.S. and China. J&J's Q3 results point to solid medical device performance, and stronger than expected iPhone demand for both the 11 and legacy models "should buoy positive headline momentum" heading into Apple's earnings at the end of the month, Coster tells investors in a research note.
10/16/19
ATLE
10/16/19
UPGRADE
Target $129
ATLE
Neutral
Johnson & Johnson upgraded to Neutral from Underweight at Atlantic Equities
Atlantic Equities analyst Steve Chesney upgraded Johnson & Johnson to Neutral from Underweight with a $129 price target.

TODAY'S FREE FLY STORIES

WFC

Wells Fargo

$53.80

0.3 (0.56%)

, AAPL

Apple

$265.73

3.07 (1.17%)

10:01
11/16/19
11/16
10:01
11/16/19
10:01
Periodicals
Berkshire Hathaway inactive with record cash hoard, Barron's says »

Berkshire Hathaway…

WFC

Wells Fargo

$53.80

0.3 (0.56%)

AAPL

Apple

$265.73

3.07 (1.17%)

OXY

Occidental Petroleum

$38.94

1.18 (3.13%)

BRK.B

Berkshire Hathaway

$219.74

0.38 (0.17%)

BRK.A

Berkshire Hathaway

$329,361.11

266.11 (0.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Jan

DIS

Disney

$144.63

-2.56 (-1.74%)

09:43
11/16/19
11/16
09:43
11/16/19
09:43
Periodicals
Disney+ may not be able to hold onto huge number of subs, Barron's says »

While Disney's (DIS)…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$112.11

2.9 (2.66%)

09:27
11/16/19
11/16
09:27
11/16/19
09:27
Periodicals
Medtronic shares 'could rise even more,' Barron's says »

Barron's recommended…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

BR

Broadridge

$119.80

0.485 (0.41%)

09:18
11/16/19
11/16
09:18
11/16/19
09:18
Periodicals
Broadridge a defensive name that can withstand slowdown, Barron's says »

Broadridge Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MCD

McDonald's

$193.95

-0.02 (-0.01%)

, MDT

Medtronic

$112.11

2.9 (2.66%)

09:07
11/16/19
11/16
09:07
11/16/19
09:07
Periodicals
Barron's suggests dividend stocks for retirement savers »

In this week's…

MCD

McDonald's

$193.95

-0.02 (-0.01%)

MDT

Medtronic

$112.11

2.9 (2.66%)

KO

Coca-Cola

$52.67

0.03 (0.06%)

PRU

Prudential

$93.61

0.82 (0.88%)

SYF

Synchrony

$37.05

0.34 (0.93%)

KEY

KeyCorp

$18.96

0.1 (0.53%)

T

AT&T

$39.49

0.53 (1.36%)

AMGN

Amgen

$220.84

2.29 (1.05%)

CSCO

Cisco

$45.10

0.18 (0.40%)

RCL

Royal Caribbean

$117.91

2.69 (2.33%)

MRK

Merck

$84.89

0.33 (0.39%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

JPM

JPMorgan

$129.51

0.83 (0.65%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 18

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 02

    Dec

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 14

    Jan

  • 21

    Jan

  • 23

    Jan

  • 24

    Jan

  • 24

    Jan

  • 29

    Jan

  • 05

    Feb

  • 12

    Feb

  • 14

    Mar

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

, MSFT

Microsoft

$149.95

1.89 (1.28%)

08:54
11/16/19
11/16
08:54
11/16/19
08:54
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AMZN

Amazon.com

$1,737.49

-17.22 (-0.98%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

AAPL

Apple

$265.73

3.07 (1.17%)

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

THC

Tenet

$30.55

1.08 (3.66%)

GM

General Motors

$36.87

0.07 (0.19%)

FCAU

Fiat Chrysler

$16.02

0.04 (0.25%)

TM

Toyota

$144.29

1.16 (0.81%)

F

Ford

$8.96

0.16 (1.82%)

HMC

Honda

$28.99

0.155 (0.54%)

VWAGY

Volkswagen

$0.00

(0.00%)

BMWYY

BMW

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 09

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 04

    Feb

  • 06

    Feb

MDCO

The Medicines Co.

$51.92

1.03 (2.02%)

04:55
11/16/19
11/16
04:55
11/16/19
04:55
Conference/Events
Roth Capital pharmaceuticals analysts to hold a luncheon »

Analysts host Dr. John…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

CVET

Covetrus

$14.93

1.44 (10.67%)

18:41
11/15/19
11/15
18:41
11/15/19
18:41
Hot Stocks
Covetrus CEO: We're a leader in the humanization of pets »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCSK

Comcast

$0.00

(0.00%)

, CMCSA

Comcast

$44.54

-0.93 (-2.05%)

18:02
11/15/19
11/15
18:02
11/15/19
18:02
Hot Stocks
Viacom extends cable deal for 'The Office' through 2025 »

Viacom (VIA) announced…

CMCSK

Comcast

$0.00

(0.00%)

CMCSA

Comcast

$44.54

-0.93 (-2.05%)

VIAB

Viacom

$23.07

0.59 (2.62%)

VIA

Viacom

$26.59

1.28 (5.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CWK

Cushman & Wakefield

$19.10

0.1 (0.53%)

17:48
11/15/19
11/15
17:48
11/15/19
17:48
Hot Stocks
Cushman & Wakefield CEO sells 84.6K share of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LMT

Lockheed Martin

$393.52

3.305 (0.85%)

17:39
11/15/19
11/15
17:39
11/15/19
17:39
Hot Stocks
Lockheed Martin awarded maximum $3.33B Air Force contract »

Lockheed Martin has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ESCA

Escalade

$10.90

-0.09 (-0.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Escalade CEO Fetherman to retire »

Escalade announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.96

0.1 (0.78%)

, ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

17:38
11/15/19
11/15
17:38
11/15/19
17:38
Hot Stocks
Eldorado, Caesars stockholders approve Eldorado acquisition of Caesars »

Eldorado Resorts (ERI)…

CZR

Caesars

$12.96

0.1 (0.78%)

ERI

Eldorado Resorts

$52.10

0.93 (1.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

EGRX

Eagle Pharmaceuticals

$57.24

0.55 (0.97%)

17:15
11/15/19
11/15
17:15
11/15/19
17:15
Syndicate
Breaking Syndicate news story on Eagle Pharmaceuticals »

Eagle Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FN

Fabrinet

$60.82

0.84 (1.40%)

17:11
11/15/19
11/15
17:11
11/15/19
17:11
Hot Stocks
Fabrinet President Gill sells 12.9K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

TEUM

Pareteum

$0.38

-0.0209 (-5.21%)

17:05
11/15/19
11/15
17:05
11/15/19
17:05
Hot Stocks
Pareteum receives noncompliance notice from Nasdaq »

Pareteum announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HEXO

Hexo

$1.78

-0.1 (-5.32%)

17:00
11/15/19
11/15
17:00
11/15/19
17:00
Hot Stocks
Hexo was cannabis was being grown in unlicensed space at Niagara site »

HEXO Corp provided…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMGN

Amgen

$220.84

2.29 (1.05%)

, CELG

Celgene

$110.02

-0.01 (-0.01%)

16:57
11/15/19
11/15
16:57
11/15/19
16:57
Hot Stocks
Bristol-Myers gets FTC clearance for Celgene acquisition »

Bristol-Myers Squibb…

AMGN

Amgen

$220.84

2.29 (1.05%)

CELG

Celgene

$110.02

-0.01 (-0.01%)

BMY

Bristol-Myers

$58.61

0.11 (0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Nov

  • 04

    Dec

  • 07

    Dec

  • 25

    Mar

  • 04

    Apr

RAVE

Rave Restaurant

$1.44

-0.79 (-35.43%)

16:47
11/15/19
11/15
16:47
11/15/19
16:47
Hot Stocks
BBRC Asset Management reports 6.6% passive stake in Rave Restaurant »

BBRC Asset Management …

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CHAP

Chaparral Energy

$0.89

-0.0521 (-5.52%)

16:46
11/15/19
11/15
16:46
11/15/19
16:46
Hot Stocks
Chaparral Energy receives continued listing standard notice from NYSE »

Chaparral Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

16:45
11/15/19
11/15
16:45
11/15/19
16:45
General news
Breaking General news story  »

San Francisco Federal…

CI

Cigna

$196.08

6.41 (3.38%)

, CNC

Centene

$57.57

2.91 (5.32%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
On The Fly
Fly Intel: Wall Street's top stories for Friday »

Stocks closed out the…

CI

Cigna

$196.08

6.41 (3.38%)

CNC

Centene

$57.57

2.91 (5.32%)

CVS

CVS Health

$74.27

1.34 (1.84%)

HUM

Humana

$335.43

17.48 (5.50%)

UNH

UnitedHealth

$269.44

13.68 (5.35%)

WCG

WellCare

$312.01

10.155 (3.36%)

HNT

Health Net

$0.00

(0.00%)

MOH

Molina Healthcare

$129.60

7.3 (5.97%)

ANTM

Anthem

$298.18

16.14 (5.72%)

HCA

HCA Healthcare

$137.98

3.51 (2.61%)

CYH

Community Health

$3.12

0.25 (8.71%)

LPNT

LifePoint

$0.00

(0.00%)

UHS

Universal Health

$144.30

3.13 (2.22%)

NVDA

Nvidia

$204.12

-5.76 (-2.74%)

AMZN

Amazon.com

$1,739.33

-15.38 (-0.88%)

MSFT

Microsoft

$149.95

1.89 (1.28%)

UAA

Under Armour

$17.78

0.65 (3.79%)

UA

Under Armour

$15.97

0.41 (2.64%)

AMRN

Amarin

$23.99

2.5 (11.63%)

JNJ

Johnson & Johnson

$134.97

3.99 (3.05%)

GOOG

Alphabet

$1,334.01

21.82 (1.66%)

GOOGL

Alphabet Class A

$1,333.33

23.54 (1.80%)

ORCL

Oracle

$56.43

0.33 (0.59%)

RH

RH

$188.73

13.535 (7.73%)

QGEN

Qiagen

$40.56

3.255 (8.73%)

FTCH

Farfetch

$9.66

2.17 (28.97%)

THC

Tenet

$30.55

1.08 (3.66%)

TORC

resTORbio

$1.10

-6.83 (-86.13%)

ACB

Aurora Cannabis

$2.72

-0.57 (-17.33%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 20

    Nov

  • 22

    Nov

  • 04

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 13

    Dec

  • 28

    Dec

  • 06

    Jan

  • 21

    Jan

  • 06

    Feb

NYT

New York Times

$31.60

0.44 (1.41%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
New York Times CEO sells 66,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

WEX

Wex

$200.52

4.61 (2.35%)

16:41
11/15/19
11/15
16:41
11/15/19
16:41
Hot Stocks
Wex director Morris sells 3K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.